Matinas BioPharma (MTNB) AI Stock Analysis

• Market Cap: $4.73M
• Dividend Yield: N/A
• Average Volume (3M): 268.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: -100.00%
• EPS Growth: 5.43%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 5,086,985
• 10 Day Avg. Volume: 505,408
• 30 Day Avg. Volume: 268,387
• PEG Ratio: -0.01
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.39
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: -1.94
• Enterprise Value/Gross Profit: -2.16
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

The overall score reflects significant financial challenges due to declining revenues and persistent losses. Positive technical indicators provide some optimism, while valuation remains unattractive with a negative P/E ratio and no dividend yield. The recent board appointments may offer strategic improvements, but substantial progress is needed to improve financial health and stock performance.

Positive Factors

Clinical Study Launch

Once a partner is secured, the company will shift focus towards launching its P3 ORALTO study of MAT2203 in IA patients.

Innovative Drug Delivery

MAT2203 is an application of Matinas's lipid nanocrystal (LNC) delivery that makes amphotericin available by oral administration and has demonstrated safety at high doses for sustained periods of time.

Partnership Agreement

Matinas announced it entered a non-binding agreement with an undisclosed partner for global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections.

Negative Factors

Financial Health

The company lacks funds to materially advance any programs forward.

Leadership Changes

Matinas is implementing 80% workforce reduction, eliminating 15 positions, including departure of the CMO, CBO and CTO.

Strategic Partnership

Partnering negotiations for its lead asset MAT2203 were terminated by the prospective partner.

Matinas BioPharma Business Overview & Revenue Model

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

How the Company Makes Money

Matinas BioPharma generates revenue through the development and commercialization of its proprietary lipid nano-crystal (LNC) delivery technology. The company engages in research collaborations and license agreements to advance its drug delivery platform, which can enhance the therapeutic effectiveness of existing pharmaceuticals. Revenue is primarily derived from licensing fees, milestone payments, and potential royalties from partnerships with other biotech and pharmaceutical companies. Additionally, Matinas may receive funding from grants or government programs aimed at advancing medical research and innovation. The company's earnings are influenced by the success of its clinical trials, the establishment of strategic partnerships, and the progression of its product pipeline towards commercialization.

Matinas BioPharma Financial Statement Overview

Summary

Matinas BioPharma faces significant financial challenges, with declining revenues and persistent losses affecting its profitability and overall financial health. The balance sheet indicates declining equity and asset values, while cash flow metrics highlight difficulties in generating cash from operations. Strategic changes may be necessary to improve financial performance and stability.

Income Statement

The company has experienced a declining trend in total revenue over the years, with revenue dropping to zero in 2024. The gross profit margin remains negative, indicating cost challenges, and the net profit margin is also negative, reflecting the company's continuous losses. EBIT and EBITDA margins are in the negative territory, showcasing persistent operational challenges. The revenue growth rate is also negative, suggesting declining business activity.

Balance Sheet

The company has a moderate debt-to-equity ratio, indicating manageable leverage. However, the consistent decrease in stockholders' equity and total assets raises concerns about the company's financial stability. The equity ratio is relatively stable but declining, signaling potential risks in maintaining financial health.

Cash Flow

Operating cash flow remains negative, reflecting challenges in generating cash from operations. The free cash flow is also negative, indicating an inability to cover capital expenditures and operational needs. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income into cash. However, the company has managed some positive cash inflows from financing activities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
962.00K	0.00	1.10M	3.19M	33.33K	158.33K
	Gross Profit
-241.00K	0.00	-13.39M	-13.49M	-748.16K	-14.20M
	EBIT
-16.20M	-24.59M	-23.77M	-24.59M	-24.73M	-24.21M
	EBITDA
-15.47M	-23.36M	-22.82M	-24.23M	-24.45M	-23.92M
	Net Income Common Stockholders
-20.08M	-24.25M	-22.94M	-13.02M	-21.17M	-20.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
27.77M	7.28M	13.76M	28.76M	49.62M	58.68M
	Total Assets
40.24M	12.64M	25.10M	44.82M	61.33M	70.97M
	Total Debt
4.23M	2.89M	3.56M	4.12M	4.70M	3.75M
	Net Debt
-17.94M	-4.39M	-1.23M	-2.71M	-16.33M	-8.68M
	Total Liabilities
7.19M	5.05M	5.86M	8.18M	8.83M	7.24M
	Stockholders Equity
33.05M	7.59M	19.25M	36.64M	52.49M	63.73M
Cash Flow		Free Cash Flow
-12.12M	-15.88M	-15.50M	-20.05M	-15.48M	-17.37M
	Operating Cash Flow
-12.12M	-15.88M	-15.28M	-19.16M	-15.22M	-17.37M
	Investing Cash Flow
7.21M	9.21M	13.24M	4.88M	16.77M	-40.67M
	Financing Cash Flow
10.77M	9.17M	-7.00K	79.00K	6.96M	48.05M

Matinas BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Positive. The current price of 0.88 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 0.67, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 69.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTNB.

Matinas BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
MTNB	45 Neutral	$4.73M	―	-192.85%	―	-100.00%	5.43%
INM	44 Neutral	$3.46M	―	-91.71%	―	-11.94%	56.72%
GLTO	29 Underperform	$4.35M	―	-91.32%	―	―	48.81%
GLMD	28 Underperform	$3.41M	―	-49.58%	―	―	71.41%
QNRX	25 Underperform	$5.19M	―	-138.80%	―	―	42.26%
SNPX		$3.35M	―	-89.46%	―	―	―

Matinas BioPharma Corporate Events

Matinas BioPharma Amends Bylaws and Sets Annual Meeting

On April 30, 2025, Matinas BioPharma Holdings, Inc. amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of the voting power, aiming to facilitate the holding of such meetings. Additionally, the company amended employment agreements for key executives Jerome D. Jabbour and Keith Kucinski, introducing cash retention bonuses in the event of a change in control by March 31, 2026. The company also announced June 23, 2025, as the date for its 2025 annual stockholders meeting, with a record date set for May 1, 2025, and provided deadlines for stockholder proposals and board nominations.

Spark’s Take on MTNB Stock

According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.

The overall score reflects significant financial challenges due to declining revenues and persistent losses. Positive technical indicators provide some optimism, while valuation remains unattractive with a negative P/E ratio and no dividend yield. The recent board appointments may offer strategic improvements, but substantial progress is needed to improve financial health and stock performance.

To see Spark’s full report on MTNB stock, click here.

Matinas BioPharma Chairman Eric Ende Resigns

On March 13, 2025, Eric Ende announced his resignation from the Board of Directors and as Chairman of Matinas BioPharma, effective March 14, 2025, due to other professional commitments. His departure was not due to any disagreement or shift in the company’s direction, indicating stability in the company’s strategic focus and operations.

Matinas BioPharma Strengthens Board with New Appointments

On March 11, 2025, Matinas BioPharma announced the appointment of Keith Murphy and Edward Neugeboren to its Board of Directors, following the resignations of Natasha Giordano and Matthew Wikler due to other professional obligations. The new appointees bring extensive experience in the biotech and pharmaceutical industries, which is expected to enhance the company’s strategic direction and shareholder value. The appointments are part of Matinas BioPharma’s ongoing efforts to strengthen its leadership team as it continues to advance its innovative therapies.

Matinas BioPharma Board Member Herbert Conrad Resigns

On February 5, 2025, Herbert Conrad announced his resignation from Matinas BioPharma’s Board of Directors, effective February 6, 2025, citing retirement as his reason. His departure, which includes leaving his roles on the Audit and Nominating and Corporate Governance Committees, was not due to any disagreement or strategic shift within the company.